Aurora Cannabis Inc. has revealed its openness to considering an acquisition bid from a U.S. cannabis company looking to take over the Edmonton-based company. This development comes as Curaleaf Holdings Inc. disclosed its intentions to make a bid to acquire all shares of Aurora, prompting Aurora to establish a dedicated committee to assess the unsolicited offer.
If successful, this move would result in the formation of a joint cannabis entity operating in 17 countries across Europe, North America, and other global markets, according to Curaleaf. The Stamford, Conn.-based company, listed on the Toronto Stock Exchange, decided to make its bid public after unsuccessful attempts to engage privately with Aurora’s leadership.
Curaleaf alleged that despite sending a formal letter of intent on June 23 and a subsequent follow-up letter on July 7 outlining their proposal, Aurora’s board declined to enter into discussions. Boris Jordan, Curaleaf’s CEO, expressed disappointment at Aurora’s refusal to engage meaningfully, leading Curaleaf to communicate directly with Aurora’s shareholders due to the perceived benefits of the deal.
In response, Aurora claimed to have received the letters from Curaleaf but disputed the assertion that it rejected engaging with the offer. Aurora’s lead independent director reportedly maintained communication with Curaleaf’s CEO until July 24, emphasizing Aurora’s commitment to its current business strategy and not discouraging future dialogue.
Aurora plans to establish a special committee of independent directors to evaluate the proposal’s merits and its impact on stakeholders, emphasizing that a deal is not guaranteed, and business operations will continue as usual. While acknowledging Curaleaf’s interest, Aurora believes the current offer undervalues its long-term potential, citing its market leadership, product portfolio, financial strength, and regulatory expertise as factors contributing to greater future value creation.
Curaleaf’s proposal aims to merge the companies to leverage Curaleaf’s global distribution network with Aurora’s strong international medical cannabis presence and production capabilities. The companies collectively generated over $1.5 billion US in revenue in the past year, with Curaleaf anticipating cost synergies of at least $40 million US annually from the potential acquisition.
Jordan views the merger as a mutually beneficial opportunity for both Curaleaf and Aurora shareholders, offering them access to a diversified global platform and exposure to favorable U.S. regulatory trends.